Roland Blanqué
Galapagos (France)(FR)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Immune Response and Inflammation, Bone Metabolism and Diseases, Cytokine Signaling Pathways and Interactions, Osteoarthritis Treatment and Mechanisms
Most-Cited Works
- → A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone loss(2006)137 cited
- → Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis(2017)137 cited
- → Discovery and Optimization of an Azetidine Chemical Series As a Free Fatty Acid Receptor 2 (FFA2) Antagonist: From Hit to Clinic(2014)109 cited
- → Targeting of αv-Integrins in Stem/Progenitor Cells and Supportive Microenvironment Impairs Bone Metastasis in Human Prostate Cancer(2011)107 cited
- → Hypothermia as an indicator of the acute effects of lipopolysaccharides: comparison with serum levels of IL1β, IL6 and TNFα(1996)67 cited
- → Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis(2021)54 cited
- → Identification of a 4-(Hydroxymethyl)diarylhydantoin as a Selective Androgen Receptor Modulator(2012)51 cited
- → Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial(2020)43 cited
- → Bone-Resorbing Cytokines from Peripheral Blood Mononuclear Cells after Hormone Replacement Therapy: A Longitudinal Study(2001)36 cited
- → Pharmacological characterization of GLPG1972/S201086, a potent and selective small-molecule inhibitor of ADAMTS5(2021)25 cited